These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

684 related items for PubMed ID: 19330725

  • 1. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
    Milani C, Castillo J.
    Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
    [Abstract] [Full Text] [Related]

  • 2. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
    Bosly A, Keating MJ, Stasi R, Bradstock K.
    Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR, Bonavida B.
    Oncogene; 2005 Mar 24; 24(13):2121-43. PubMed ID: 15789036
    [Abstract] [Full Text] [Related]

  • 7. Rituximab in chronic lymphocytic leukemia.
    Jaglowski SM, Byrd JC.
    Semin Hematol; 2010 Apr 24; 47(2):156-69. PubMed ID: 20350663
    [Abstract] [Full Text] [Related]

  • 8. [Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
    Aurer I, Mitrović Z, Radman I, Kovacević-Metelko J, Nemet D, Serventi-Seiwerth R, Stern-Padovan R, Jakic-Razumović J, Nola M, Zupancić-Salek S, Sertić D, Labar B.
    Lijec Vjesn; 2004 Apr 24; 126(11-12):307-11. PubMed ID: 16082888
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
    Cooper N, Evangelista ML, Amadori S, Stasi R.
    Curr Opin Hematol; 2007 Nov 24; 14(6):642-6. PubMed ID: 17898569
    [Abstract] [Full Text] [Related]

  • 11. Rituximab: a new monoclonal antibody therapy for non-Hodgkin's lymphoma.
    Kosits C, Callaghan M.
    Oncol Nurs Forum; 2000 Nov 24; 27(1):51-9. PubMed ID: 10660923
    [Abstract] [Full Text] [Related]

  • 12. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
    Zhou Z, Yang R.
    Crit Rev Oncol Hematol; 2008 Jan 24; 65(1):21-31. PubMed ID: 17681784
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM.
    J Clin Oncol; 2003 Aug 15; 21(16):3051-9. PubMed ID: 12837807
    [Abstract] [Full Text] [Related]

  • 17. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
    Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3982S-90S. PubMed ID: 14506197
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High-dose rituximab therapy in chronic lymphocytic leukemia.
    Keating M, O'Brien S.
    Semin Oncol; 2000 Dec 01; 27(6 Suppl 12):86-90. PubMed ID: 11226005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.